Lipid metabolism disorders: diagnosis and treatment

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Texto integral

Acesso é fechado

Sobre autores

Olga Mubarakshina

Voronezh State Medical University n.a. N.N. Burdenko

Autor responsável pela correspondência
Email: mubarakshina@mail.ru
ORCID ID: 0000-0001-6799-6322

Cand. Sci. (Med.)

Rússia, Voronezh

Olga Zhdanova

Voronezh State Medical University n.a. N.N. Burdenko

Email: olga.vr9@yandex.ru
ORCID ID: 0000-0002-3917-0395
Código SPIN: 1235-9770

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Clinical Pharmacology

Rússia, Voronezh

Bibliografia

  1. Нарушения липидного обмена. Клинические рекомендации. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/752_1 [Lipid metabolism disorders. Clinical guidelines. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/752_1 (In Russ.)].
  2. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине. под ред. П. Либби и др.; пер. с англ. под общ. ред. Р.Г. Оганова. В 4-х т. Том 1. М.: Логосфера, 2012. 596 с.: ил. [Braunwald’s heart disease: a textbook of cardiovascular medicine. Ed. by P. Libby et al.; translation from English. General editor R.G. Oganov. In 4 volumes. Volume 1. Moscow: Logosfera, 2012. 596 p.: ill. (In Russ.)].
  3. Liu J., et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids in Health and Disease. 2013;12(1):1–11.
  4. Amarenco P., Labreuche J.. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology. 2009;8(5):453–463.
  5. Ershova A., Balakhonova T., Meshkov A., et al. Carotid and femoral artery plaques as predictors of cardiovascular and all-cause mortality in the middle-aged general population. Atherosclerosis Supplements. 2022;355:e43–e44. doi: 10.1016/j.atherosclerosis.2022.06.212.
  6. Ежов М.В., Бажан С.С., Ершова А.И. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58–98. [Ezhov M.V., Bazhan S.S., Ershova A.I., et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58–98. (In Russ.)].
  7. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–2454.
  8. Holewijn S., et al. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Int Med. 2010;268(6):567–577.
  9. Blonde L., Umpierrez G.E., Reddy S.S., et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. doi: 10.1016/j.eprac.2022.08.002.
  10. Pletcher M.J., et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Int Med. 2004;164(12):1285–1292.
  11. Балахонова Т.В., Ершова А.И., Ежов М.В. и др. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi: 10.15829/1728-8800-2022-3333.
  12. Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013;129(25 suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1
  13. Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056/NEJMoa1800389.
  14. Oscarsson J., Önnerhag K., Riserus U., et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018 Nov-Dec;12(6):1390–1403.e4. doi: 10.1016/j.jacl.2018.08.003.
  15. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008;101(12):1689–93. doi: 10.1016/j.amjcard.2008.02.056.
  16. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database System Rev. 2013. doi: 10.1002/14651858.cd004816.pub5.
  17. Vallejo-Vaz A.J., et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138(8):770–781.
  18. Bohula E.A., Wiviott S.D., Giugliano R.P., et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017;136:2440–2450. doi: 10.1161/CIRCULATIONAHA.117.029095.
  19. Schreml J., Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Current medicinal chemistry. 2018;25(13):1538–1548.
  20. Klebs S., Lecocq J., Mann С., et al. Characterization of Inclisiran Use in Real World: Prescription Data from Germany. J Clin Lipidol. 2022;16(3):Suppl e73. doi: 10.1016/j.jacl.2022.05.060.
  21. Rohit D., Shankar J. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol Clin Sci. 2016;5(1):25–31.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. DIAGNOSTICS OF DYSLIPDEMIA

Baixar (730KB)
Metadados
3. TREATMENT OF LIPID METABOLISM DISORDERS

Baixar (696KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2025